Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo

Oncology Letters
Bao-Lai ZhangWenkai Zhang

Abstract

Protein arginine methyltransferases (PRMTs) are a class of epigenetic modified enzymes that are overexpressed in a various types of cancer and serve pivotal functions in malignant transformation. Arginine methyltransferase inhibitor-1 (AMI-1) is a symmetrical sulfonated urea that inhibits the activity of type I PRMT in vitro. However, previous studies demonstrated that AMI-1 may also inhibit the activity of type II PRMT5 in vitro. To the best of our knowledge, the present study provides the first evidence that AMI-1 may significantly inhibit the viability of mouse sarcoma 180 (S180) and human osteosarcoma U2OS cells. Additionally, the results demonstrated that AMI-1 downregulated the activities of PRMT5, the symmetric dimethylation of histone 4 and histone 3 (a PRMT5-specific epigenetic mark) in a mouse xenograft model of S180 and induced apoptosis in S180 cells. Taken together, the results suggest that AMI-1 may exhibit antitumor effects against sarcoma cells by targeting PRMT5.

References

Oct 25, 2001·Blood·I Herr, K M Debatin
Feb 5, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eduardo AnsorenaMatías A Avila
Apr 2, 2004·The Journal of Biological Chemistry·Donghang ChengMark T Bedford
May 4, 2005·Molecular Cell·Mark T Bedford, Stéphane Richard
Nov 7, 2007·Nature Structural & Molecular Biology·Sukesh R BhaumikAli Shilatifard
Nov 18, 2008·Nature Cell Biology·Martin JanssonNicholas B La Thangue
Jan 20, 2009·Molecular Cell·Mark T Bedford, Steven G Clarke
Jun 29, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·George D DemetriUNKNOWN National Comprehensive Cancer Network Soft Tissue Sarcoma Panel
Jan 14, 2012·The Journal of Biological Chemistry·Cecilia I Zurita-LopezSteven G Clarke
May 25, 2012·Expert Opinion on Therapeutic Targets·Boksik Cha, Eek-Hoon Jho
Dec 14, 2012·Nature Reviews. Cancer·Yanzhong Yang, Mark T Bedford
Jan 8, 2013·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Xiangxiang BaoXingsheng Yang
Mar 22, 2014·Cancer Cell·Patricia A J Muller, Karen H Vousden
Oct 21, 2014·PloS One·Aliny Pereira LimaElisângela de Paula Silveira-Lacerda
Oct 2, 2015·Oncoscience·Yan Li, J Alan Diehl
Oct 16, 2015·Oncotarget·Xiaolan DengRyuji Hamamoto
Mar 31, 2016·Experimental Hematology·Sarah M GreenblattStephen D Nimer
Aug 25, 2016·Oncotarget·Coralie PoulardMuriel Le Romancer
Nov 14, 2016·International Journal of Biological Macromolecules·Li MoYong Zhan
May 23, 2017·Oncology Letters·Fuminori SonoharaShuji Nomoto
Oct 11, 2017·Toxicology and Applied Pharmacology·Baolai ZhangNengqian Ma

❮ Previous
Next ❯

Citations

Jul 3, 2021·International Journal of Molecular Sciences·Khuloud BajboujQutayba Hamid
Jul 3, 2021·Cells·Miguel Esperança-MartinsSérgio Dias

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
xenograft

Software Mentioned

Gel
SPSS
CurveExpert
FCSDiva
Pro Analyzer

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.